Not for human consumption, diagnostic, therapeutic, or veterinary use
Semaglutide is still being studied for its effects on long-term health, and patients are encouraged to talk to their doctors about any concerns they may have
Include a letter of medical necessity from your provider, documentation of all qualifying comorbidities, evidence of failed prior weight loss attempts, and any supporting metabolic data
Competitive intensity is intensifying as Eli Lillys tirzepatide prompts Novo Nordisk to expand its oral formulations and dose strengths, thereby heightening the focus on manufacturing scale, supply security, and patient-centric delivery formats
Importantly, there is no FDA indication specifically for semaglutide use after bariatric surgery, making this an off-label application
This route opens the door for more people to access these powerful therapies safely and consistently under medical guidance